Selective inhibition of rock1 in cardiac therapy
AssigneeBaylor College of Medicine
InventorsLei Wei, Robert Schwartz, Jiang Chang, Mark Entman
Life of this patent
Estimating the term…
Abstract
The present invention is directed to the treatment and/or prevention of disease as it relates to Rho kinase. In specific embodiments, disease is treated and/or prevented through the administration of an agent that selectively inhibits ROCK1. In specific embodiments, it inhibits ROCK1 and not ROCK2. In other specific embodiments, the disease is cardiac disease.
Claims30
A method of preventing or delaying apoptosis of a cell, comprising the step of delivering an agent to the cell, wherein said agent selectively inhibits ROCK1 and wherein said agent comprises a nucleic acid, polypeptide, peptide, or mixture thereof.
A method of treating cardiac failure in an individual, said cardiac failure the direct or indirect result of cleavage of Rho kinase in at least one cardiac cell of the individual, comprising administering to the individual a therapeutically effective amount of an agent that selectively inhibits ROCK1, wherein said agent comprises a nucleic acid, polypeptide, peptide, or mixture thereof.
Dependencies are inferred from the claim text.